Josun And Josun Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -80.64%
(FY 2021)
- Profit -606.63%
(FY 2021)
- Ebitda -570.78%
(FY 2021)
- Net Worth -78.52%
(FY 2021)
- Total Assets -29.28%
(FY 2021)
About Josun And Josun Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Priyank Porecha, Dixit Kajavdara, Imran Ali, and One other member serve as directors at the Company.
- CIN/LLPIN
U36994MH2017PTC302373
- Company No.
302373
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Dec 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Josun And Josun Pharmaceutical?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyank Porecha  | Director | 03-May-2024 | Current |
| Dixit Kajavdara | Director | 03-May-2024 | Current |
| Imran Ali | Director | 20-Jan-2018 | Current |
| Khursheed Ahmad | Director | 01-Dec-2017 | Current |
Financial Performance and Corporate Structure Insights of Josun And Josun Pharmaceutical.
Josun And Josun Pharmaceutical Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 80.64% decrease. The company also saw a substantial fall in profitability, with a 606.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 78.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Josun And Josun Pharmaceutical?
In 2021, Josun And Josun Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Josun And Josun Pharmaceutical?
Unlock and access historical data on people associated with Josun And Josun Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Josun And Josun Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Josun And Josun Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
